University of Auckland’s Rain Therapeutics has priced shares at $17 each to raise $125m in its initial public offering.
Rain Therapeutics, a US-based precision oncology therapeutics developer based on research at University of Auckland, priced its shares at $17 each today to raise $125m in an initial public offering.
The company issued more than 7.35 million shares and will trade on the Nasdaq Global Select Market using the ticker symbol RAIN.
Founded in 2017, Rain Therapeutics is working on tumour-agnostic precision oncology treatments.
It licensed tarloxotinib from Auckland and previously considered the drug its…
